With a massive yield of 4.5%, solid dividend growth, and the potential that shares are 22% undervalued, Pfizer $PFE looks like one of the better long-term opportunities in the market for dividend growth investors. See @JasonFieber latest UDGSOW analysis. https://t.co/DBUzJuWwj5 https://t.co/RiRfnkLmkf